Axis-Shield launches anti-CCP arthritis test on new analyser
This article was originally published in Clinica
Axis-Shield and Technogenetics have launched an anti-cyclic citrullinated peptide (CCP) test, which runs on Technogenetics' Zenit RA system, outside the US. Axis-Shield's anti-CCP assays, which are designed to detect rheumatoid arthritis (RA) at an early stage, are already available on several other platforms including Bio-Rad Laboratories' BioPlex 2200 and Abbott's Architect family of analysers. The new test and system will be marketed by Italian firm Menarini, which has exclusive European distribution rights. CCP antibodies can appear in patients' blood before the onset of arthritis symptoms, and Axis-Shield claims that anti-CCP testing is more specific than rheumatoid factor, a traditional RA diagnostic.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.